Muscular Dystrophy Trial, Recruiting NCT07543016 Sponsor: University of Pavia Condition: Muscular Dystrophy
Back to Muscular Dystrophy

Muscular Dystrophy Trial, Recruiting

NCT07543016
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Facioscapulohumeral Muscular Dystrophy (FSHD), confirmed by a genetic test
  • You are between 18 and 50 years old
  • Your FSHD has been classified into a specific group that includes the most typical signs of the disease, such as weakness in the face and shoulder muscles (confirm with trial site)
  • Your condition falls within a certain range on a clinical scoring system, scored between 2 and 5 (confirm with trial site)
  • You are still able to walk at the time of joining the trial
  • You have no problems affecting your brain or nerves, based on your medical history and a physical check-up
  • You do not have a curved spine (scoliosis), tightening of the joints in your limbs, or shortened tendons

Who may not be able to join:

  • You are currently taking beta-blocker medications (a type of heart or blood pressure medicine)
  • You have a psychological or psychiatric condition
  • You have a muscle or joint injury that stops you from doing physical exercise
  • You have recently changed your medications, or you take drugs that affect tiredness or wakefulness (such as Modafinil or amantadine)
  • You are currently taking part in another clinical trial, or finished one less than 30 days ago
  • You are pregnant or breastfeeding
  • You are not able to fully understand the study or give your consent to take part
  • You have other health conditions that could affect the study's measurements
  • You are under legal guardianship or do not have full legal freedom (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +39 0383 62053

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Pavia
Registry
ClinicalTrials.gov
Start date
8 April 2026
Est. completion
1 November 2028

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Change in fat mass in FSHD; Change in fat-free mass in FSHD; Change in aerobic capacity in FSHD; Change in muscle strength in FSHD; Change in walking performance in FSHD

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov